Effect of steroid use in anterior cervical discectomy and fusion: a randomized controlled trial

Shiveindra B. Jeyamohan, MD, Tyler J. Kenning, MD, Karen A. Petronis, NP, Paul J. Feustel, PhD, Doniel Drazin, MD, and Darryl J. DiRisio, MD

Department of Neurosurgery, Albany Medical College, Albany, New York

OBJECT Anterior cervical discectomy and fusion (ACDF) is an effective procedure for the treatment of cervical radiculopathy and/or myelopathy; however, postoperative dysphagia is a significant concern. Dexamethasone, although potentially protective against perioperative dysphagia and airway compromise, could inhibit fusion, a generally proinflammatory process. The authors conducted a prospective, randomized, double-blinded, controlled study of the effects of steroids on swallowing, the airway, and arthrodesis related to multilevel anterior cervical reconstruction in patients who were undergoing ACDF at Albany Medical Center between 2008 and 2012. The objective of this study was to determine if perioperative steroid use improves perioperative dysphagia and airway edema.

METHODS A total of 112 patients were enrolled and randomly assigned to receive saline or dexamethasone. Data gathered included demographics, functional status (including modified Japanese Orthopaedic Association myelopathy score, neck disability index, 12-Item Short-Form Health Survey score, and patient-reported visual analog scale score of axial and radiating pain), functional outcome swallowing scale score, interval postoperative imaging, fusion status, and complications/reoperations. Follow-up was performed at 1, 3, 6, 12, and 24 months, and CT was performed 6, 12, and 24 months after surgery for fusion assessment.

RESULTS Baseline demographics were not significantly different between the 2 groups, indicating adequate randomization. In terms of patient-reported functional and pain-related outcomes, there were no differences in the steroid and placebo groups. However, the severity of dysphagia in the postoperative period up to 1 month proved to be significantly lower in the steroid group than in the placebo group (p = 0.027). Furthermore, airway difficulty and a need for intubation trended toward significance in the placebo group (p = 0.057). Last, fusion rates at 6 months proved to be significantly lower in the steroid group but lost significance at 12 months (p = 0.048 and 0.57, respectively).

CONCLUSIONS Dexamethasone administered perioperatively significantly improved swallowing function and airway edema and shortened length of stay. It did not affect pain, functional outcomes, or long-term swallowing status. However, it significantly delayed fusion, but the long-term fusion rates remained unaffected.

Clinical trial registration no.: NCT01065961 (clinicaltrials.gov)

KEY WORDS cervical spine; dysphagia; fusion; steroid; dexamethasone
been controlled with steroid administration. Recent evidence further suggests that local steroid placement during surgery also helps with swelling and odynophagia.

Steroids given intraoperatively and postoperatively may lower the incidence of these adverse outcomes by reducing the degree of swelling within the anterior neck after local surgical tissue trauma. This effect is likely a result of the antiinflammatory properties of steroids, which serve to inhibit the release of inflammatory mediators and decrease capillary permeability. The use of steroids during spinal arthrodoses procedures, however, has historically been controversial because of a concern that antiinflammatory agents could reduce the rates of fusion, a proinflammatory process.

Methods

A prospective, randomized, double-blinded, controlled study in patients who underwent multilevel (≥2 motion segments) anterior cervical spine surgery between 2008 and 2012 was conducted. The study is registered with the ClinicalTrials.gov database (http://clinicaltrials.gov), and its registration no. is NCT01065961. One hundred twelve patients were enrolled with a target follow-up of 24 months. The Albany Medical Center Institutional Review Board approved the study. Our hypothesis stated that perioperative steroid administration would decrease dysphagia and airway complications without affecting long-term fusion rates. An a priori estimate was also calculated by using a presumed (from a previous study) dysphagia rate at 6 months of 19%, with an expected reduction (based on our previous experience) to approximately 4% with steroid treatment. This calculation resulted in a power of 92% with a target of 200 patients.

Patients who fulfilled the inclusion criteria (Table 1) were randomly assigned to receive intraoperative doses of either intravenous dexamethasone (Decadron; 0.2 mg/kg) or an equivalent volume infusion of saline followed by 4 postoperative doses of 0.06 mg/kg of steroid or placebo, respectively, administered every 6 hours for the first 24 hours. The patients and the investigators were blinded to the treatment for the duration of the study. Postoperative steroid use was allowed for severe dysphagia and/or airway compromise that necessitated intubation; such deviations were recorded for consideration in the final analysis.

The following preoperative parameters were collected for each patient: baseline demographics, smoking history, pain level and functional status (modified Japanese Orthopaedic Association myelopathy scores, neck disability index, 12-Item Short-Form Health Survey [SF-12] scores, and visual analog scale [VAS] scores), swallowing function (according to the functional outcome swallowing scale [FOSS]; Table 2), and the indication for surgery. In the immediate postoperative period, the percentage of patients who reported symptoms of dysphagia or airway compromise, the quantification of dysphagia symptoms on postoperative Day 1 according to the FOSS, and the length of inpatient stay were reviewed. At the 3-, 6-, 12-, and 24-month follow-up time points, the patients were assessed by using the FOSS and pain and functional scales (modified Japanese Orthopaedic Association myelopathy scores, neck disability index, VAS scores, and SF-12 scores). Fusion status was assessed by fine-cut cervical CT scans with reconstructions obtained at 6, 12, and 24 months. The spine was considered fused if bridging osseous trabeculae were seen spanning each operative level without any intervening radiographic lucencies (Fig. 1). All postoperative complications were also noted.

Surgical Technique

The senior author (D.J.D.) performed every multilevel anterior cervical spine surgery in this study by using the Smith-Robinson technique and a right-sided approach. The Thompson-Farley static (self-retaining) retractor was used in every case. Wide discectomies were performed with a combination of curettes and a high-speed drill, with the drill being used to remove the cartilaginous endplates of the vertebral bodies until bleeding bone was identified. The interbody device used was a carbon-fiber cage filled with hydroxyapatite, Type I collagen, and autologous iliac crest bone marrow aspirate. All anterior spinal osteophytes were removed with a drill to provide a flat surface for the DePuy (Johnson and Johnson) Swift plate (3-mm thickness, 16-mm width, and 2-mm internal dynamization per level). All the procedures were conducted with intraoperative neuromonitoring, including somatosensory

<table>
<thead>
<tr>
<th>TABLE 1. Inclusion/exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion criteria</td>
</tr>
<tr>
<td>Age ≥18 yrs</td>
</tr>
<tr>
<td>Cervical spondylosis requiring surgical treatment at ≥2 motion segments</td>
</tr>
<tr>
<td>Ventrally approachable vertebral levels</td>
</tr>
<tr>
<td>Exclusion criteria</td>
</tr>
<tr>
<td>Age &lt;18 yrs</td>
</tr>
<tr>
<td>Pregnancy</td>
</tr>
<tr>
<td>Chronic preop steroid use</td>
</tr>
<tr>
<td>Coma or incapacitation, unable to provide consent</td>
</tr>
<tr>
<td>Allergy to dexamethasone or related drugs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TABLE 2. Summary of FOSS scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td>0</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
</tbody>
</table>
evoked potentials, motor evoked potentials, and upper-extremity electromyography. Postoperatively, each patient was treated with a hard cervical orthosis while upright or ambulatory for a duration of 4–6 weeks, after which time he or she was weaned from the cervical collar.

Statistical Analysis
Quantitative data are expressed in terms of mean values with corresponding standard deviations. The independent 2-sample t-test was used for comparisons of variables; statistical significance was defined as a p value of < 0.05.

Results
At the conclusion of the study, 112 patients were enrolled; 56 received dexamethasone, and 56 received saline. Forty patients received 3-level fusions, 42 received 4-level fusions, 2 received 5-level fusions, and the remaining 28 received 2-level fusions. One of the patients in the steroid group required an additional course of postoperative outpatient steroids for continued difficulties with swallowing discovered during his follow-up visit. Of the placebo group, 8 patients required steroids postoperatively, 5 for severe dysphagia and 3 for airway concerns; 3 of these 8 patients required intubation in the perioperative course. One of these patients suffered a tonsillar laceration from intubation that required steroids to manage swelling and a formal ear, nose, and throat evaluation for prolonged swallowing dysfunction. One patient in the placebo group received 1 fewer dose because of a nursing error and was included in the final analysis. Analyses were repeated after the data for these patients were removed from the analysis to adjust for the effects of postoperative steroids.

Baseline demographic differences were insignificant between the 2 groups and are outlined in Table 3. Postoperative and follow-up information is also provided in Tables 4–7, which detail pain scores, myelopathy scores, swallowing function, and fusion rates and show no significant difference except for left upper-extremity pain at 3 months. Postoperative data collection began 1 month after surgery, at which time swallowing function was assessed along with the incision, and more detailed follow-up was performed at 3, 6, 12, and 24 months. Perioperative swallowing function, as detailed by FOSS score, patient-reported dysphagia, length of stay, and airway difficulty, proved significantly worse in the placebo group than in the dexamethasone-treated group. When data for the patients who received steroids outside the protocol were removed from analysis, significance was maintained in terms of length of stay and postoperative FOSS score, patient-reported dysphagia, and airway difficulty.

Data were also analyzed at follow-up intervals (6, 12, and 24 months) to assess pain, function, swallowing function, and fusion rates. It should be noted that there were no significant differences in the myelopathy scores, axial pain scores, extremity pain scores, Oswestry Disability Index (ODI) scores, or SF-12 scores (either mental summary component or physical summary component) at these intervals.

Table 3. Comparison of demographic and baseline data

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Placebo</th>
<th>Dexe</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (% male)</td>
<td>48.22</td>
<td>58.93</td>
<td>0.26</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>55</td>
<td>54</td>
<td>0.671</td>
</tr>
<tr>
<td>% smokers</td>
<td>36.70</td>
<td>30.36</td>
<td>0.553</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.24</td>
<td>30.40</td>
<td>0.89</td>
</tr>
<tr>
<td>mJOA score</td>
<td>0.13</td>
<td>13.75</td>
<td>0.287</td>
</tr>
<tr>
<td>FOSS score</td>
<td>0.13</td>
<td>0.14</td>
<td>0.784</td>
</tr>
<tr>
<td>ODI score</td>
<td>44.04</td>
<td>42.75</td>
<td>0.805</td>
</tr>
<tr>
<td>SF-12 PCS score</td>
<td>31.65</td>
<td>33.91</td>
<td>0.215</td>
</tr>
<tr>
<td>SF-12 MCS score</td>
<td>44.94</td>
<td>42.28</td>
<td>0.118</td>
</tr>
<tr>
<td>VAS score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axial pain</td>
<td>48.60</td>
<td>43.56</td>
<td>0.37</td>
</tr>
<tr>
<td>Right-arm pain</td>
<td>32.70</td>
<td>32.70</td>
<td>0.99</td>
</tr>
<tr>
<td>Left-arm pain</td>
<td>36.40</td>
<td>37.44</td>
<td>0.95</td>
</tr>
</tbody>
</table>

BMI = body mass index; Dexe = dexamethasone; MCS = mental component summary; mJOA = modified Japanese Orthopaedic Association (scoring for myelopathy); PCS = physical component summary.
* Values are expressed as means unless noted otherwise.

Table 4. Comparison of 3-month outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Placebo</th>
<th>Dexe</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>mJOA score</td>
<td>15.66</td>
<td>16.23</td>
<td>0.315</td>
</tr>
<tr>
<td>FOSS score</td>
<td>0.261</td>
<td>0.14</td>
<td>0.445</td>
</tr>
<tr>
<td>ODI score</td>
<td>34.82</td>
<td>31.38</td>
<td>0.763</td>
</tr>
<tr>
<td>SF-12 PCS score</td>
<td>35.27</td>
<td>37.88</td>
<td>0.219</td>
</tr>
<tr>
<td>SF-12 MCS score</td>
<td>46.93</td>
<td>46.62</td>
<td>0.656</td>
</tr>
<tr>
<td>VAS score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axial pain</td>
<td>29.3</td>
<td>26</td>
<td>0.85</td>
</tr>
<tr>
<td>Right-arm pain</td>
<td>22.8</td>
<td>18.34</td>
<td>0.84</td>
</tr>
<tr>
<td>Left-arm pain</td>
<td>22.8</td>
<td>15.43</td>
<td>0.04†</td>
</tr>
</tbody>
</table>

* Values are expressed as means.
† Statistically significant.
tervals. The patients who received steroids had significantly lower fusion rates at 6 months, although by 12 months there was no difference in these rates. In the placebo group, 47 of 56 patients were followed up at 3 months, 49 of 56 at 6 months, and 41 of 56 at 12 months. In the steroid group, 46 of 56 patients were followed up at 3 months, 41 of 56 at 6 months, and 35 of 56 at 12 months. For those patients who did not attend follow-up, several of them had outpatient CT images sent to us for evaluation without a formal office visit. Other patients who underwent CT imaging for unrelated issues, typically for trauma or evaluation of neck pain in the emergency department, had their images evaluated for fusion status. Those who did not attend follow-up but who were noted in previous visits to have achieved fusion were assumed to have achieved fusion despite the lack of imaging. In the placebo group, the fusion rates at 6, 12, and 24 months were 60.0%, 80.0%, and 95.2%, respectively. FOSS scores in the steroid group were also evaluated, and although at the end of the study period there were no significant differences between the two groups, swallowing function was significantly worse in the placebo group at 1 month (0.66 vs 0.064; p = 0.027) (Fig. 2).

Discussion

In the surgical treatment of multilevel cervical pathology, potential complications of the anterior approach are often cited as the reason for selecting a posterior approach. With the extended retraction of the anterior neck structures necessitated by the anterior approach, both dysphagia and airway compromise become a significant concern. The severity and potential life-threatening nature of these complications from anterior cervical spinal surgery have prompted more thorough evaluations of their incidence and associated risk factors.\textsuperscript{3,6,9,11,13,19,24,27–29,33}

The reported rates of dysphagia after anterior cervical surgery have varied widely, from 1% to 79%.\textsuperscript{9} In a prospective study, Lee et al.\textsuperscript{19} found the prevalence of postoperative dysphagia at 1, 2, 6, 12, and 24 months to be 54%, 34%, 19%, 15%, and 14%, respectively. They concluded that postsurgical edema is probably the strongest contributor to dysphagia in the early postoperative period and that the amount of scar tissue plays a greater role than other factors in the long-term follow-up period. In addition, the more life-threatening complication of postoperative airway problems may occur in up to 6% of patients.\textsuperscript{4,9,11,29}

Kepler et al.\textsuperscript{16} also found significantly increased dysphagia and soft-tissue shadowing on postoperative radiographs after 1- and 2-level ACDFs. The swelling decreased by 6 weeks but remained significant. They also noted that the degree of soft-tissue swelling did not correlate with postoperative dysphagia.

![FIG. 2. Graph illustrating swallowing status after surgery in the placebo and steroid-treated groups. Figure is available in color online only.](image-url)
Another theoretical concern of steroid administration is infection. ACDF is known to result in significantly lower infection rates than posterior procedures,2,22 which is mirrored by the results of this study. There were no infections in either the steroid or the placebo group.

The role of steroids in the alleviation of edema in the structures of the anterior neck has been widely explored in the fields of otolaryngology, anesthesiology, and critical care medicine.12,15 The evaluation of perioperative steroid use in spinal surgery, however, has been relatively limited; only 1 study has provided Level 1 evidence.10,26,30 That study did not find a benefit for parenteral steroid use in expediting extubation after multilevel cervical corpectomy surgery.10 This paucity of data is largely a result of concern about deleterious effects on bone healing. Many investigators recommend that NSAIDs not be used in patients undergoing spinal fusion surgery.21 Although the data are generally conflicting, a large body of literature derived from laboratory studies suggests that NSAIDs either delay or inhibit bone healing.14 Regarding corticosteroids, 1 study in a rabbit model of posterior lumbar fusion showed that twice-daily injections over a 42-day period inhibited bone-graft incorporation.20

In 2011, Lee et al.20 studied the effect of local steroids, given via triamcinolone and morcellized collagen sponge in the retropharyngeal space, in a prospective randomized study. They found significantly reduced prevertebral soft-tissue swelling in the upper cervical levels on lateral radiographs obtained immediately, 2 days, and 2 weeks after surgery. Furthermore, they found reduced severity of odynophagia 2 weeks after surgery in patients who were treated with local steroids.

In another study,23 dexamethasone administered intravenously was studied to evaluate for prevertebral swelling. Intravenous placebo or dexamethasone (40 or 80 mg) was administered, and the effects were examined by using daily radiographs for 5 days and patient-reported dyspnea and dysphagia VAS scores. Although their data indicated no significant difference in prevertebral swelling between the treated and untreated groups, Nam et al.23 noted that dexamethasone helped manage the severity of dyspnea during the initial postoperative days.

Our data are results of a prospective, randomized, double-blinded trial in which we analyzed the effects of perioperative steroid use in multilevel anterior cervical spine surgery. Between the 2 subgroups of patients, those who received steroids and those who were given an equivalent dose of placebo, there were no significant differences in any of the preoperative parameters, including baseline demographics, swallowing function, and pain and functional scale scores. Furthermore, postoperatively, with the exception of 3-month left upper-extremity pain, all outcome measures proved insignificant between the placebo and dexamethasone groups. This similarity helped to ensure that the results from the steroid and placebo groups can be compared reliably.

Dysphagia

In the perioperative and 1-month postoperative periods, we found significantly lower rates of dysphagia among patients in the steroid-treated group than in those in the placebo group, which supports our hypothesis, as quantified by both the FOSS scores and the presence of any dysphagia as indicated by the patient. Also of note was that 7 of the patients in the placebo group required postoperative steroid treatment for severe dysphagia, whereas only 1 of the steroid-treated patients required continued steroids on follow-up, which also suggests the effectiveness of postoperative steroid use in controlling symptoms. This treatment consisted of dexamethasone given intravenously (10-mg bolus followed by 4 mg every 6 hours). This inference, however, may play into our inherent bias toward steroid treatment. Traditionally, our practice has noted that patients who undergo a multilevel ACDF typically remain in the hospital for concerns of dysphagia; from a pain standpoint, the operation is very well tolerated. It follows, therefore, that improved dysphagia in treated patients translated to shorter lengths of stay, which also proved significantly superior in the steroid-treated group. This result could be confounded by steroid euphoria.

Airway Compromise

The 2.7% rate of airway compromise in this study is similar to rates in previously published reports.4,5,11,29 Three patients who had significant symptoms of respiratory difficulty required intubation; all of them had been randomly assigned to the placebo group and ultimately required intravenous dexamethasone for control of airway edema. Airway issues and need for intubation trended toward significance (p = 0.057 and 0.083, respectively) and may prove significant with repeated studies in larger populations. No patient in the steroid group required intubation.

Fusion

Many spine surgeons acknowledge that corticosteroids have the potential to help limit some postoperative complications but are reluctant to use these medications routinely for fear that they may negatively impact bony fusion rates. Even in the setting of severe dysphagia or airway difficulty symptoms, there is still reluctance to use steroids for fear of these long-term effects. The results of our study show a significant difference between the placebo and steroid groups in fusion rates at 6 months (60% vs 37.8%, respectively; p = 0.046), although the differences in these rates at 12 and 24 months proved insignificant (80% vs 75% [p = 0.53] and 95.2% vs 92.7% [p = 0.57], respectively). Thus, it seems that perioperative steroids delay the fusion process without affecting patient outcomes at any point, as indicated by both pain and functional outcome measures. When data from the patients who received additional steroids in the perioperative and immediate postoperative period were removed from analysis, fusion rates at 6 months approached but did not reach significance (60.0% [placebo group] vs 39.5% [steroid group]; p = 0.064). This result may in part be a result of decreased power secondary to fewer subjects. At 12 and 24 months, fusion rates converged; the rates in the dexamethasone and placebo groups were 75% and 80% (p = 0.577) at 12 months and 95.2% and 92.7% (p = 0.63) at 24 months, respectively (Fig. 3).
tilevel cervical spine surgery. Another limitation is the and in previously published studies that examined mul-
ized, is similar to that for other therapeutic indications.

Study Limitations/Future Directions
The limitations of this study include the dexametha-
sone-dosing schedule used, which, although not standard-
ized, is similar to that for other therapeutic indications and in previously published studies that examined mul-
tilevel cervical spine surgery. Another limitation is the use of the FOSS score to quantify dysphagia symptoms. This scale has been shown to be valid and reliable, but it is clinician based and not a comprehensive measure of quality of life. Also, although generated while the surgeon was blinded to the treatment groups, the fusion rates were jointly assessed by the senior surgeon (D.J.D.) and staff neuroradiologists, which could have inflated the fusion rates. Swallowing function was also assessed by the se-
ior author. Additional limitations include the somewhat-
significant deviations from protocol; this study illustrated our inherent bias toward perhaps more liberal use of dexamethasone in the postoperative period for continued dys-
phagia. Because most significant cases of dysphagia oc-
curred in the placebo group, and all of them were treated with steroid medication, the fusion rates could have been affected. However, despite removal of these data points from the analysis, fusion rates were still significantly dif-
ferent at 6 months but insignificant at 12 months. Last, the initial goal of the study was to obtain 200 patients with 2 years of follow-up data. However, there was significant difficulty in attaining acceptable follow-up rates at the 2-year mark. Furthermore, institutional approval for the study was terminated early secondary to significant results at the midterm analysis.

Future studies could include larger sample sizes to elu-
cidate the role of steroids in potentially reducing airway compromise and the need for intubation. Furthermore, future studies could also determine the significance of fu-
donation on clinical outcome. The role of fusion status in the development of adjacent-level disease could also be studied further. Additionally, improved methods for follow-up to 2 years should be implemented as well to evaluate both fusion and functional/pain-related outcomes. Low follow-
up rates may also be partially secondary to patients seek-
ing care elsewhere during the study period.

Last, although there was no difference between lev-
els fused in both cohorts, future studies can more evenly match the number of levels fused to assist in standardizing the data.

Conclusions
Our results suggest that the use of perioperative steroids in multilevel anterior cervical surgery helps limit symp-
toms of both dysphagia and airway compromise. Although it delayed fusion in the short term, perioperative steroid use did not negatively affect long-term fusion rates.

References
1. Bagshaw SM, Delaney A, Farrell C, Drummond J, Brindley PG: Best evidence in critical care medicine. Steroids to pre-
3. Bazaz R, Lee MJ, Yoo JU: Incidence of dysphagia after ante-
5. Cabraja M, Abbushi A, Koeppehn D, Kroppenstredt S, Woiciechowsky C: Comparison between anterior and poste-
rior decompression with instrumentation for cervical spond-
gol 110:834–840, 2001
10. Emery SE, Akhavan S, Miller P, Furey CG, Yoo JU, Rowbot-
tom JR, et al: Steroids and risk factors for airway compro-
mise in multilevel cervical corpectomy patients: a prospec-
lactic administration of parenteral steroids for preventing airway complications after extubation in adults: meta-analy-
Steroid use with ACDF


Author Contributions
Conception and design: Petronis, Drazin, DiRisio. Acquisition of data: Jeyamohan, Kenning, Petronis, DiRisio. Analysis and interpretation of data: Jeyamohan, Kenning, Feustel, DiRisio. Drafting the article: Jeyamohan, Kenning, DiRisio. Critical revising the article: Jeyamohan, DiRisio. Reviewed submitted version of manuscript: Jeyamohan, DiRisio. Approved the final version of the manuscript on behalf of all authors: Jeyamohan. Statistical analysis: Jeyamohan, Kenning, DiRisio, Feustel. Administrative/technical/material support: Petronis, DiRisio. Study supervision: Petronis, DiRisio.

Supplemental Information
Current Affiliation
Dr. Drazin: Department of Neurosurgery, Spine Center, Cedars-Sinai Medical Center, Los Angeles, CA.

Correspondence
Shiveindra B. Jeyamohan, 47 New Scotland Ave., MC-10, Albany, NY 12208. email: jeyamos@mail.amc.edu.